IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
C-F Xu, T Johnson, J Garcia-Donas, TK Choueiri, CN Sternberg, ID Davis, N Bing, KC Deen, Z Xue, L McCann, E Esteban, JC Whittaker, CF Spraggs, C Rodriguez-Antona, LN Pandite, RJ Motzer
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2015
This study was funded by GlaxoSmithKline. Pfizer provided funding for the Spanish Oncology Genitourinary Group (SOGUG) sunitinib study. We thank the investigators and their patients who made this study possible. We thank Karen King and Sandy Stinnett for their help in generation and management of the genetic data. We also thank Dr Enrique Grande for his support, and all members of SOGUG for their commitment to the project. Medical editorial assistance for the manuscript was provided by Joan Hudson and Jerome F. Sah, PhD, of ProEd Communications, Inc., Beachwood, Ohio, and was funded by GlaxoSmithKline, Philadelphia, Pennsylvania.